Pasar al contenido principal

CARACTERIZACION DE DETERMINANTES GENETICOS RELEVANTES PARA EL DESARROLLO DE UNA VACUNA FRENTE AL VIRUS DE LA PESTE PORCINA AFRICANA

RTI2018-097305-R-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario INSTITUTO NACIONAL DE INVESTIGACIÓN Y TECNOLOGÍA AGRARIA Y ALIMENTARIA - CSIC

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

COVID-19: Drug targets and potential treatments

  • Gil, Carmen
  • Ginex, Tiziana
  • Maestro, Inés
  • Nozal, Vanesa
  • Barrado-Gil, Lucía
  • Cuesta-Geijo, Miguel Ángel
  • Urquiza, Jesús
  • Ramírez, David
  • Alonso Martí, Covadonga
  • Campillo, Nuria E.
  • Martínez Gil, Ana
92 p.-22 fig.-1 tab.-1 graph. abst., Currently, we are immersed in a pandemic caused by the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which severely threatens public health worldwide. Until now, no drug or vaccine has been approved to treat the severe disease caused by this coronavirus, COVID-19. We will focus on the main virus-based and host-based targets that can guide medicinal chemistry efforts to discover new drugs for this devastating disease. In principle, all CoVs enzymes and proteins involved in viral replication and the control of host cellular machineries are potentially druggable targets in the search for therapeutic options for SARS-CoV-2. This perspective provides an overview of the main targets from a structural point of view, together with reported therapeutic compounds with activity against SARS-CoV-2 and/or other CoVs. Also, the role of innate immune response to coronavirus infection and the related therapeutic options will be presented., Funding from CSIC (201980E024 and 202020E103) is acknowledged. This research was partially supported through "la Caixa" Banking Foundation (HR18-00469), Instituto de Salud Carlos III (ISCIII-COV20/01007), Spanish Ministry of Science and Innovation (RTI2018-097305-R-I00), CONICYT-PCI (REDES190074 to D. R. and A. M.) and FONDECYT (11180604 to D.R.). I. M. was funded by H2020-MSCA-ITN-2017 (grant no. 765912), V. N. holds a pre-doctoral FPU grant (FPU16/04466) and J. U. was financed by FPI-SGIT2018-04., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Antiviral drugs targeting endosomal membrane proteins inhibit distant animal and human pathogenic viruses

  • Galindo Estrada, Ignacio
  • Garaigorta, Urtzi
  • Lasala, Fátima
  • Cuesta-Geijo, Miguel Ángel
  • Bueno, P.
  • Gil, Carmen
  • Delgado, Rafael
  • Gastaminza, Pablo
  • Alonso Martí, Covadonga
The endocytic pathway is a common strategy that several highly pathogenic viruses use to enter into the cell. To demonstrate the usefulness of this pathway as a common target for the development of broad-spectrum antivirals, the inhibitory effect of drug compounds targeting endosomal membrane proteins were investigated. This study entailed direct comparison of drug effectiveness against animal and human pathogenic viruses, namely Ebola (EBOV), African swine fever virus (ASFV), and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A panel of experimental and FDA-approved compounds targeting calcium channels and PIKfyve at the endosomal membrane caused potent reductions of entry up to 90% in SARS-CoV-2 S-protein pseudotyped retrovirus. Similar inhibition was observed against transduced EBOV glycoprotein pseudovirus and ASFV. SARS-CoV-2 infection was potently inhibited by selective estrogen receptor modulators in cells transduced with pseudovirus, among them Raloxifen inhibited ASFV with very low 50% inhibitory concentration. Finally, the mechanism of the inhibition caused by the latter in ASFV infection was analyzed. Overall, this work shows that cellular proteins related to the endocytic pathway can constitute suitable cellular targets for broad range antiviral compounds., This research was partially supported through “La Caixa” Banking Foundation (HR18-00469), Instituto de Salud Carlos III (FIS PI 181007 and ISCIII-COV20/01007), CSIC (201980E024 and 202020E079), Spanish Ministry of Science and Innovation (RTI2018-097305-R-I00) and the European Commission Horizon 2020 Framework Programme VACDIVA-SFS-12-2019-1-862874. PB is supported by a grant of Comunidad de Madrid PEJD-2019-PRE/BMD-16764., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Identification of NPC1 as a novel SARS-CoV-2 intracellular target

  • García-Dorival, Isabel
  • Cuesta-Geijo, Miguel Ángel
  • Barrado-Gil, Lucía
  • Galindo, Inmaculada
  • Urquiza, Jesús
  • Puerto, Ana del
  • Gil, Carmen
  • Campillo, Nuria E.
  • Martínez Gil, Ana
  • Alonso, Covadonga
Niemann-Pick type C1 (NPC1) receptor is an endosomal membrane protein that regulates intracellular cholesterol trafficking, which is crucial in the Ebola virus (EBOV) cycle. The severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) enters the cell by binding of the viral spike (S) protein to the ACE2 receptor. This requires S-protein processing either by the surface transmembrane serine protease TMPRSS2 for plasma membrane fusion or cathepsin L for endosomal entry. Additional host factors are required for viral fusion at endosomes. Here, we report a novel interaction of the SARS-CoV-2 nucleoprotein (N) with the cholesterol transporter NPC1. Moreover, small molecules interfering with NPC1 that inhibit EBOV entry, also inhibited human coronavirus. Our findings suggest an important role for NPC1 in SARS-CoV-2 infection, a common strategy shared with EBOV, and a potential therapeutic target to fight against COVID-19., This research was partially supported through “La Caixa” Banking Foundation (HR18-00469), Instituto de Salud Carlos III (ISCIII-COV20/01007), CSIC (201980E024 and 202020E079), Spanish Ministry of Science and Innovation (RTI2018-097305-R-I00) and the European Commission Horizon 2020 Framework Programme VACDIVA-SFS482 12-2019-1-862874., No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Identification of potential inhibitors of protein-protein interaction useful to fight against Ebola and other highly pathogenic viruses

  • Lasala, Fátima
  • García-Rubia, Alfonso
  • Requena, Carlos
  • Galindo Barreales, Inmaculada
  • Cuesta-Geijo, Miguel Ángel
  • García-Dorival, Isabel
  • Bueno, P.
  • Labiod, Nuria
  • Luczkowiak, Joanna
  • Martínez Gil, Ana
  • Campillo, Nuria E.
  • Alonso Martí, Covadonga
  • Delgado, Rafael
  • Gil, Carmen
16 p.-1 fig.-1 tab., Despite the efforts to develop new treatments against Ebola virus (EBOV) there is currently no antiviral drug licensed to treat patients with Ebola virus disease (EVD). Therefore, there is still an urgent need to find new drugs to fight against EBOV. In order to do this, a virtual screening was done on the druggable interaction between the EBOV glycoprotein (GP) and the host receptor NPC1 with a subsequent selection of compounds for further validation. This screening led to the identification of new small organic molecules with potent inhibitory action against EBOV infection using lentiviral EBOV-GP-pseudotype viruses. Moreover, some of these compounds have shown their ability to interfere with the intracellular cholesterol transport receptor NPC1 using an ELISA-based assay. These preliminary results pave the way to hit to lead optimization programs that lead to successful candidates., Funding from “la Caixa” Banking Foundation under the project code HR18-00469 is acknowledged. This research was partially supported through Instituto de Salud Carlos III (FIS PI 181007 and ISCIII-COV20/01007), CSIC (201980E024 and 202020E079), Spanish Ministry of Science and Innovation (RTI2018-097305-R-I00) and the European Commission Horizon 2020 Framework Programme (Project VIRUSCAN FETPROACT-2016 and VACDIVA-SFS-12-2019-1-862874)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Potential pharmacological strategies targeting the Niemann-Pick C1receptor and Ebola virus glycoprotein interaction

  • Morales-Tenorio, Marcos
  • Ginex, Tiziana
  • Cuesta-Geijo, Miguel Ángel
  • Campillo, Nuria E.
  • Muñoz-Fontela, César
  • Alonso Martí, Covadonga
  • Delgado, Rafael
  • Gil, Carmen
12 p.-5 fig.-2 tab.-1 graph. abst., Niemann-Pick C1 (NPC1) receptor is an intracellular protein located in late endosomes and lysosomes whose main function is to regulate intracellular cholesterol trafficking. Besides being postulated as necessary for the infection of highly pathogenic viruses in which the integrity of cholesterol transport is required, this protein also allows the entry of the Ebola virus (EBOV) into the host cells acting as an intracellular receptor. EBOV glycoprotein (EBOV-GP) interaction with NPC1 at the endosomal membrane triggers the release of the viral material into the host cell, starting the infective cycle. Disruption of the NPC1/EBOV-GP interaction could represent an attractive strategy for the development of drugs aimed at inhibiting viral entry and thus infection. Some of the today available EBOV inhibitors were proposed to interrupt this interaction, but molecular and structural details about their mode of action are still preliminary thus more efforts are needed to properly address these points. Here, we provide a critical discussion of the potential of NPC1 and its interaction with EBOV-GP as a therapeutic target for viral infections., The project leading to these results has received funding from “la Caixa” Banking Foundation under the project code LCF/PR/HR19/52160012. This research was partially supported through the Spanish Ministry of Science and Innovation (RTI2018-097305-R-I00), the Instituto de Investigación Carlos III, ISCIII, (FIS PI 1801007) and the European Commission Horizon 2020 Framework Programme Project VIRUSCAN FETPROACT-2016: 731868. M. M. holds a pre-doctoral FPU grant (FPU18/03493) from MICINN., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Identification of Niemann-Pick C1 protein as a potential novel SARS-CoV-2 intracellular target

  • García-Dorival, Isabel
  • Cuesta-Geijo, Miguel Ángel
  • Barrado-Gil, Lucía
  • Galindo Barreales, Inmaculada
  • Garaigorta, Urtzi
  • Urquiza, Jesús
  • Puerto, Ana del
  • Campillo, Nuria E.
  • Martínez Gil, Ana
  • Gastaminza, Pablo
  • Gil, Carmen
  • Alonso Martí, Covadonga
10 p.-4 fig., Niemann-Pick type C1 (NPC1) receptor is an endosomal membrane protein that regulates intracellular cholesterol traffic. This protein has been shown to play an important role for several viruses. It has been reported that SARS-CoV-2 enters the cell through plasma membrane fusion and/or endosomal entry upon availability of proteases. However, the whole process is not fully understood yet and additional viral/host factors might be required for viral fusion and subsequent viral replication. Here, we report a novel interaction between the SARS-CoV-2 nucleoprotein (N) and the cholesterol transporter NPC1. Furthermore, we have found that some compounds reported to interact with NPC1, carbazole SC816 and sulfides SC198 and SC073, were able to reduce SARS-CoV-2 viral infection with a good selectivity index in human cell infection models. These findings suggest the importance of NPC1 for SARS-CoV-2 viral infection and a new possible potential therapeutic target to fight against COVID-19., This research was partially supported through “La Caixa” Banking Foundation (LCF/PR/HR19/52160012), Instituto de Salud Carlos III (ISCIII–COV20/01007), the Spanish Ministry of Science and Innovation (RTI2018-097305-R-I00), CSIC (PIE-RD-COVID-19 refs. E201980E024 and E202020E079) and the European Union-NextGenerationEU. EVA (European Virus Archive; grant agreement No 871029)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

New insights into the role of endosomal proteins for African swine fever virus infection

  • Cuesta-Geijo, Miguel Ángel
  • García-Dorival, Isabel
  • Puerto, Ana del
  • Urquiza, Jesús
  • Galindo Barreales, Inmaculada
  • Barrado-Gil, Lucía
  • Lasala, Fátima
  • Cayuela, Ana
  • Sorzano, Carlos Óscar S.
  • Gil, Carmen
  • Delgado, Rafael
  • Alonso Martí, Covadonga
28 p.-7 fig.-- Departamento de Biotecnología., African swine fever virus (ASFV) infectious cycle starts with the viral adsorption and entry into the host cell. Then, the virus is internalized via clathrin/dynamin mediated endocytosis and macropinocytosis. Similar to other viruses, ASF virion is then internalized and incorporated into the endocytic pathway. While the endosomal maturation entails luminal acidification, the decrease in pH acts on the multilayer structure of the virion dissolving the outer capsid. Upon decapsidation, the inner viral membrane is exposed to interact with the limiting membrane of the late endosome for fusion. Viral fusion is then necessary for the egress of incoming virions from endosomes into the cytoplasm, however this remains an intriguing and yet essential process for infection, specifically for the egress of viral nucleic acid into the cytoplasm for replication. ASFV proteins E248R and E199L, located at the exposed inner viral membrane, might be implicated in the fusion step. An interaction between these viral proteins and cellular endosomal proteins such as the Niemann-Pick C type 1 (NPC1) and lysosomal membrane proteins (Lamp-1 and -2) was shown. Furthermore, the silencing of these proteins impaired ASFV infection. It was also observed that NPC1 knock-out cells using CRISPR jeopardized ASFV infection and that the progression and endosomal exit of viral cores was arrested within endosomes at viral entry. These results suggest that the interactions of ASFV proteins with some endosomal proteins might be important for the membrane fusion step. In addition to this, reductions on ASFV infectivity and replication in NPC1 KO cells were accompanied by fewer and smaller viral factories. Our findings pave the way to understanding the role of proteins of the endosomal membrane in ASFV infection., This research was partially supported through the following awards: “La Caixa” Banking Foundation award number LCF/PR/HR19/52160012, Spain, https://fundacionlacaixa.org/en/ to CA and RD, Spanish Ministry of Science and Innovation, Spain RTI2018-097305-R- I00, https://www.ciencia.gob.es/ to CA, Instituto de Investigación Carlos III, ISCIII, Spain FIS PI 1801007, https://www.isciii.es/ to RD, European Commission, Horizon 2020 Framework Programme European Union ASFVInt ERANET-2021-862605 to CA, co-funded by Spanish Ministry of Science and Innovation, Spain PCI2021-121939 https://www.ciencia.gob.es/ to CA, VIRUSCAN FETPROACT-2016- 731868 and EPIC-CROWN-2-2021-101046084 https://ec.europa.eu/ to RD., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

African Swine Fever Virus Ubiquitin-Conjugating Enzyme Is an Immunomodulator Targeting NF-κB Activation

  • Barrado-Gil, Lucía
  • Puerto, Ana del
  • Galindo Barreales, Inmaculada
  • Cuesta-Geijo, Miguel Ángel
  • García-Dorival, Isabel
  • de Motes, Carlos Maluquer
  • Alonso Martí, Covadonga
African swine fever virus (ASFV) is an acute and persistent swine virus with a high economic burden that encodes multiple genes to evade host immune response. In this work, we have revealed that early viral protein UBCv1, the only known conjugating enzyme encoded by a virus, modulates innate immune and inflammatory signaling. Transient overexpression of UBCv1 impaired activation of NF-κB and AP-1 transcription factors induced by several agonists of these pathways. In contrast, activation of IRF3 and ISRE signaling upon stimulation with TRIFΔRIP, cGAS/STING or RIG-I-CARD remained unaltered. Experiments aimed at mapping UBCv1 inhibitory activity indicated that this viral protein acts upstream or at the level step of IKKβ. In agreement with this, UBCv1 was able to block p65 nuclear translocation upon cytokine stimulation, a key event in NF-ĸB signaling. Additionally, A549 stably transduced for UBCv1 showed a significant decrease in the levels of NF-ĸB dependent genes. Interestingly, despite the well-defined capacity of UBCv1 to conjugate ubiquitin chains, a mutant disabled for ubiquitylation activity retained similar immunomodulatory activity as the wild-type enzyme, suggesting that the two functions are segregated. Altogether these data suggest that ASFV UBCv1 manipulates the innate immune response targeting the NF-κB and AP-1 pathways and opens new questions about the multifunctionality of this enzyme., This research was partially supported through “La Caixa” Banking Foundation award number LCF/PR/HR19/52160012, Spain and the Ministry of Science and Innovation grants AGL2015- 69598-R and RTI2018-097305-R-I00., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Effect of Clinically Used Microtubule Targeting Drugs on Viral Infection and Transport Function

  • Oliva, María A.
  • Tosat-Bitrian, Carlota
  • Barrado-Gil, Lucía
  • Bonato, Francesca
  • Galindo Barreales, Inmaculada
  • Garaigorta, Urtzi
  • Álvarez-Bernad, Beatriz
  • París-Ogáyar, Rebeca
  • Lucena-Agell, Daniel
  • Giménez-Abián, Juan F.
  • García-Dorival, Isabel
  • Urquiza, Jesús
  • Gastaminza, Pablo
  • Díaz, José Fernando
  • Palomo, Valle
  • Alonso Martí, Covadonga
Microtubule targeting agents (MTAs) have been exploited mainly as anti-cancer drugs because of their impact on cellular division and angiogenesis. Additionally, microtubules (MTs) are key structures for intracellular transport, which is frequently hijacked during viral infection. We have analyzed the antiviral activity of clinically used MTAs in the infection of DNA and RNA viruses, including SARS-CoV-2, to find that MT destabilizer agents show a higher impact than stabilizers in the viral infections tested, and FDA-approved anti-helminthic benzimidazoles were among the most active compounds. In order to understand the reasons for the observed antiviral activity, we studied the impact of these compounds in motor proteins-mediated intracellular transport. To do so, we used labeled peptide tools, finding that clinically available MTAs impaired the movement linked to MT motors in living cells. However, their effect on viral infection lacked a clear correlation to their effect in motor-mediated transport, denoting the complex use of the cytoskeleton by viruses. Finally, we further delved into the molecular mechanism of action of Mebendazole by combining biochemical and structural studies to obtain crystallographic high-resolution information of the Mebendazole-tubulin complex, which provided insights into the mechanisms of differential toxicity between helminths and mammalians., This work was supported by Ministerio de Ciencia e Innovación PID2019-104545RBI00/ AEI/10.13039/501100011033 to JFD and RTI2018-097305-R-I00 to CA, Consejo Superior de Investigaciones Científicas PIE 201920E111 to JFD, PIE 202020E301 and the European Commission– NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI Salud Global) to JFD and CA, H2020-MSCA-ITN-2019 860070 TUBINTRAIN to JFD, “La Caixa” Banking Foundation (LCF/PR/HR19/52160012) to CA, Postdoctoral Junior Leader Fellowship Programme from ‘La Caixa’ Banking Foundation (LCF/BQ/PR18/11640007) to VP and Ministerio de Ciencia e Innovacion FPI program (PRE2020-094384) to BAB and Ministerio de Educación FPU program (FPU18/06310) to CTB. We also acknowledge a generous donation from Club Deportivo Escuela Hungaresa de Pontevedra., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

African Swine Fever Virus Ubiquitin-Conjugating Enzyme Interacts With Host Translation Machinery to Regulate the Host Protein Synthesis

  • Barrado-Gil, Lucía
  • Puerto, Ana del
  • Muñoz-Moreno, Raquel
  • Galindo Barreales, Inmaculada
  • Cuesta-Geijo, Miguel Ángel
  • Urquiza, Jesús
  • Nistal-Villán, Estanislao
  • Maluquer de Motes, Carlos
  • Alonso Martí, Covadonga
15 Pág., African Swine Fever virus (ASFV) causes one of the most relevant emerging diseases affecting swine, now extended through three continents. The virus has a large coding capacity to deploy an arsenal of molecules antagonizing the host functions. In the present work, we have studied the only known E2 viral-conjugating enzyme, UBCv1 that is encoded by the I215L gene of ASFV. UBCv1 was expressed as an early expression protein that accumulates throughout the course of infection. This versatile protein, bound several types of polyubiquitin chains and its catalytic domain was required for enzymatic activity. High throughput mass spectrometry analysis in combination with a screening of an alveolar macrophage library was used to identify and characterize novel UBCv1-host interactors. The analysis revealed interaction with the 40S ribosomal protein RPS23, the cap-dependent translation machinery initiation factor eIF4E, and the E3 ubiquitin ligase Cullin 4B. Our data show that during ASFV infection, UBCv1 was able to bind to eIF4E, independent from the cap-dependent complex. Our results provide novel insights into the function of the viral UBCv1 in hijacking cellular components that impact the mTORC signaling pathway, the regulation of the host translation machinery, and the cellular protein expression during the ASFV lifecycle., This research was partially supported through Spanish Ministry of Science and Innovation under Award Number RTI2018-097305-R-I00. Funding from “la Caixa” Banking Foundation under the project code HR18-00469 and EU H2020 VACDIVA SFS-12-2019-862874 is acknowledged. Fellowship Award FPI references BES-2013-066610 and BES 2010-036950 funded B-GL and RM-M Work in EN-V. laboratory was funded by project NIETO-CM B2017/BMD 3731 and in CM laboratory was funded by the United Kingdom Biotechnology and Biological Sciences Research Council (grant ref. BB/M003647/1)., Peer reviewed